Dynomics - Human-predictive discovery to unlock precision cardiac therapeutics

Decoding Heart Function

Human-predictive discovery to unlock precision cardiac therapeutics

Cardiovascular Disease

Cardiovascular disease remains the largest cause of mortality and healthcare costs, yet most therapies only address risk factors or disease symptoms, rather than improving heart function.

US Prevalence
45%
of 2035 population
Treatment options are limited and remain primarily symptomatic
Burden
1 in 3
deaths
Heart failure alone affects more than 64 million people worldwide

Precision Cardiology is Emerging

New genetic and functional insights are enabling precision therapies that can address disease drivers and improve patient heart function

Past

Drugging Risk Factors

map

Future

Drugging Heart Function

However, so far there is a lack of well-characterized precision drug targets that have been genetically and functionally validated in humans.

Current Cardiac Discovery Lacks Human Predictivity

IN VITRO

Introducing HeartDyno®

We built HeartDyno, our human cardiac tissue discovery platform, to decode heart function. It identifies novel drug targets, new therapeutics, and  target patient populations.

Authentic
Representative cardiac cell composition
Mature
Highest published maturity level
Scalable
Thousands of uniform tissues per week
IN SILICO

Powered by Tempo.ai

Our cloud based in silico system captures and QCs HeartDyno® functional data, learns signatures of cardiac function, and integrates multi-omics to de-convolute molecular effectors of cardiac contractility.

AI-driven quality control
Augments the scalability of HeartDyno® with human-supervised QC models
Functional Machine Learning
Functional signatures cluster into distinct classes of drug/target biology.
Predictive Clinical Relevance
Molecular benchmarking against standards enable predictive models of safety and efficacy.

Our Discovery Engine

Uniting cardiac function with multi-omics to map new targets, therapies, and patient populations in precision cardiology.

Multi-omic dataset mining to identify new target/therapeutic concept
1
Genetic validation
2
Functional validation assay
3
Patient population matching with disease model library
4
Predictive model benchmarking
5

Pipeline

We are advancing a diversified portfolio of therapeutic assets discovered and de-risked with HeartDyno®.

Closing The Innovation Gap

Enabling human-predictive, precision cardiac drug discovery